3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 1
6
Phase 3
4
Phase 1/2
3
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
5
Melphalan
4
Isotretinoin
4
Etoposide
4
Carboplatin
4
Vincristine
3
Therapeutics
3
Radiotherapy
3
Cisplatin
3
Topotecan
2
Stem Cell Transplantation
2
Radiotherapy, Image-Guided
2
Psychiatric Rehabilitation
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Granulocyte Colony-Stimulating Factor
2
Doxorubicin
2
Dexamethasone
2
Calcium Dobesilate
2
Busulfan
2
Blood Specimen Collection
2
Aprepitant
2
3-Iodobenzylguanidine
2
sargramostim
1
pegfilgrastim
1
humanized 3F8 anti-GD2 monoclonal antibody
1
hetrombopag
1
etoposide phosphate
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Whole-Body Irradiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Neuroblastoma
×
sargramostim
×
Clear all
NCT02786719
2020-03-12
SPRING
Baylor College of Medicine
Phase NA
Completed
13 enrolled
13 charts